Latin America In Vitro Diagnostics (IVD) Market Analysis By Product (Instruments, Reagents, Software), By Technology (Immunochemistry, Hematology, Clinical Chemistry, Coagulation, Microbiology, Molecular Diagnostics), By Application (Infectious Diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune Diseases, Drug Testing), By End-use (Hospitals, Laboratory, Home Care), And Segment Forecasts To 2024

Published: Aug, 2016 | Pages: 78 | Publisher: Grand View Research
Industry: Biotechnology | Report Format: Electronic (PDF)

The latin america IVD market is expected to reach over USD 5.1 billion by 2024, according to a new report by Grand View Research, Inc. The Latin America IVD market is expected to grow at a significant CAGR till 2024 owing to the rising prevalence of target disorders, aging population, and the presence of favorable government initiatives for early disease diagnosis. Other factors that are anticipated to boost the growth include the introduction of technologically advanced instruments and the increasing R&D initiatives for the development of disease-specific kits.

Regular testing for diabetes, cardiovascular, cancer, and sexually transmitted diseases are necessary for the timely treatments, further avoiding the risk of fatal health complications. The availability of tests for home and near patient testing is estimated to further enhance the usage rates of these devices. From November 2015, the Anvisa, which is a regulatory body for medical devices in Brazil, has started allowing the registration for HIV self-testing kits.

The increasing adoption point of care devices coupled with the increasing awareness among the healthcare professionals regarding the early diagnosis of various diseases has provided a boost to the Latin IVD market. The rising epidemic of communicable diseases in the southernpart of Latin America, the growing need for rapid and accurate diagnostics, and the changing healthcare infrastructure scenario are some of the key drivers of the Latin IVD market.

Further key findings from the study suggest:

The instrument segment is one of the most important segments of in vitro diagnostics. The presence of highly automated analyzers and the availability of over the counter products are some of the factors responsible for its significant share.

The Molecular diagnostics segment is anticipated to be the fastest growing technology over the decade. Molecular diagnostics is a transformative area of diagnostics. The continuous innovation in technology helps the physicians for critical decision making

The infectious disease segment held the largest share in 2015 over 24% owing to the presence of favorable government initiatives in association with the WHO to curb communicable diseases.

The home care segment is estimated to witness a significant growth over the forecast period. The high number of R&D initiatives undertaken by key competitors for the development of portable IVD devices with improved sensitivity and user-friendliness is a key factor attributing towards its growth.

In 2015, Brazil was the largest regional segment with a revenue generation of over USD 1.2 billion owing to the established healthcare infrastructure, growing awareness for cancer screening, and the increasing demand for genetic testing.

Peru is expected to be one of the fastest growing regions on account of the growing economic stability, high unmet clinical needs, and the rising disposable incomes

Key players operating in the Latin America IVD market are Roche Diagnostics, Abbott Laboratories, Inc., Hologic (Gen-Probe), Becton Dickinson (BD) Company, Alere, Inc., Bio-Rad Laboratories, Qiagen N.V., Inc., bioMerieux, BioQuidel Corporation, and Siemens Healthcare.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Latin America IVD Market- Industry Snapshot and Key Buying Criteria, 2015
Chapter 3. Latin America IVD Industry Outlook
3.1. Latin America IVD Market Segmentation
3.2. Latin America IVD Market Size and Growth Outlook
3.3. Latin America IVD Market Dynamics
3.3.1. Market Drivers Estimates
3.3.1.1. Substantial Increase in Geriatric Population in Latin America
3.3.1.2. Considerable Prevalence of Chronic Disease
3.3.1.3. Growing Need for Point of Care Facilities.
3.3.2. Market Restraint Estimates
3.3.2.1. Lesser Rate of Reimbursement
3.3.2.2. Stringent Regulatory Background
3.4. Market Estimates - Porter's
3.5. Latin America IVD Market PESTEL Estimates, 2015
Chapter 4. Latin America IVD Product Outlook
4.1. Latin America IVD Market Share by Product, 2015 & 2024
4.2. Instruments
4.2.1. Instruments Market Estimates and Forecasts, 2013 - 2024
4.3. Reagents
4.3.1. Reagents Market Estimates and Forecasts, 2013 - 2024
4.4. Software
4.4.1. Software Market Estimates and Forecasts, 2013 - 2024
Chapter 5. Latin America IVD Technology Outlook
5.1. Latin America IVD Market Share by technology, 2015 & 2024
5.2. Immunochemistry
5.2.1. Immunochemistry Market Estimates and Forecasts, 2013 - 2024
5.3. Hematology
5.3.1. Hematology Market Estimates and Forecasts, 2013 - 2024
5.4. Clinical Chemistry
5.4.1. Clinical Chemistry Market Estimates and Forecasts, 2013 - 2024
5.5. Molecular Diagnostics
5.5.1. Molecular Diagnostics Market Estimates and Forecasts, 2013 - 2024
5.6. Coagulation
5.6.1. Coagulation Market Estimates and Forecasts, 2013 - 2024
5.7. Microbiology
5.7.1. Microbiology Market Estimates and Forecasts, 2013 - 2024
5.8. Other Clinical Technology
5.8.1. Other Clinical Technology Market Estimates and Forecasts, 2013 - 2024
Chapter 6. Latin America IVD Application Outlook
6.1. Latin America IVD Market Share by Application, 2015 & 2024
6.2. Infectious Disease
6.2.1. Infectious Disease Market Estimates and Forecasts, 2013 - 2024
6.3. Diabetes
6.3.1. Diabetes Market Estimates and Forecasts, 2013 - 2024
6.4. Oncology/Cancer
6.4.1. Oncology/Cancer Market Estimates and Forecasts, 2013 - 2024
6.5. Cardiology
6.5.1. Cardiology Market Estimates and Forecasts, 2013 - 2024
6.6. Nephrology
6.6.1. Nephrology Market Estimates and Forecasts, 2013 - 2024
6.7. Autoimmune Diseases
6.7.1. Autoimmune Diseases Market Estimates and Forecasts, 2013 - 2024
6.8. Drug Testing
6.8.1. Drug Testing Market Estimates and Forecasts, 2013 - 2024
6.9. Others
6.9.1. Others Market Estimates and Forecasts, 2013 - 2024
Chapter 7. Latin America IVD End-use Outlook
7.1. Latin America IVD Market Share by End-use, 2015 & 2024
7.2. Hospitals
7.2.1. Hospitals Market Estimates and Forecasts, 2013 - 2024
7.3. Laboratory
7.3.1. Laboratory Market Estimates and Forecasts, 2013 - 2024
7.4. Home Care
7.4.1. Home Care Market Estimates and Forecasts, 2013 - 2024
7.5. Others
7.5.1. Others Market Estimates and Forecasts, 2013 - 2024
Chapter 8. Latin America IVD Regional Outlook
8.1. Latin America Market Share by Region, 2015 & 2024
8.2. Brazil
8.2.1. Brazil IVD Market, 2013 - 2024 (USD Million)
8.3. Mexico
8.3.1. Mexico IVD Market, 2013 - 2024 (USD Million)
8.4. Peru
8.4.1. Peru IVD Market, 2013 - 2024 (USD Million)
8.5. Chile
8.5.1. Chile IVD Market, 2013 - 2024 (USD Million)
8.6. Colombia
8.6.1. Colombia IVD Market, 2013 - 2024 (USD Million)
8.7. Argentina
8.7.1. Argentina IVD Market, 2013 - 2024 (USD Million)
8.8. Venezuela
8.8.1. Venezuela IVD Market, 2013 - 2024 (USD Million)
Chapter 9. Competitive Landscape
9.1. Becton Dickinson
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiatives
9.2. bioMerieux
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Strategic Initiatives
9.3. Abbott Laboratories
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Strategic Initiatives
9.4. Quidel Corporation
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Strategic Initiatives
9.5. Alere, Inc.
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Strategic Initiatives
9.6. OraSure Technologies
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Strategic Initiatives
9.7. Hologic (Gen Probe)
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Strategic Initiatives
9.8. Cepheid Inc.
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Strategic Initiatives
9.9. Qiagen N.V.
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Strategic Initiatives
9.10. Roche Diagnostics
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Benchmarking
9.10.4. Strategic Initiatives
9.11. Siemens Healthcare
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Product Benchmarking
9.11.4. Strategic Initiatives
9.12. Bio-Rad Laboratories
9.12.1. Company Overview
9.12.2. Financial Performance
9.12.3. Product Benchmarking
9.12.4. Strategic Initiatives

List of Tables


TABLE 1 Latin America IVD market, - Industry Summary & Key Buying Criteria, 2013 - 2024
TABLE 2 Latin America IVD market, by product, 2013 - 2024 (USD million)
TABLE 3 Latin America IVD market, by application, 2013 - 2024 (USD million)
TABLE 4 Latin America IVD market, by technology, 2013 - 2024 (USD million)
TABLE 5 Latin America IVD market, by end-use, 2013 - 2024 (USD million)
TABLE 6 Latin America IVD market, by region, 2013 - 2024 (USD million)
TABLE 7 Latin America IVD Market, - Key market driver analysis
TABLE 8 Latin America IVD Market, - Key market restraint analysis
TABLE 9 Brazil IVD market, by product, 2013 - 2024 (USD million)
TABLE 10 Brazil IVD market, by application, 2013 - 2024 (USD million)
TABLE 11 Brazil IVD market, by technology, 2013 - 2024 (USD million)
TABLE 12 Brazil IVD market, by end-use, 2013 - 2024 (USD million)
TABLE 13 Mexico IVD market, by product, 2013 - 2024 (USD million)
TABLE 14 Mexico IVD market, by application, 2013 - 2024 (USD million)
TABLE 15 Mexico IVD market, by technology, 2013 - 2024 (USD million)
TABLE 16 Mexico IVD market, by end-use, 2013 - 2024 (USD million)
TABLE 17 Peru IVD market, by product, 2013 - 2024 (USD million)
TABLE 18 Peru IVD market, by application, 2013 - 2024 (USD million)
TABLE 19 Peru IVD market, by technology, 2013 - 2024 (USD million)
TABLE 20 Peru IVD market, by end-use, 2013 - 2024 (USD million)
TABLE 21 Chile IVD market, by product, 2013 - 2024 (USD million)
TABLE 22 Chile IVD market, by application, 2013 - 2024 (USD million)
TABLE 23 Chile IVD market, by technology, 2013 - 2024 (USD million)
TABLE 24 Chile IVD market, by end-use, 2013 - 2024 (USD million)
TABLE 25 Colombia IVD market, by product, 2013 - 2024 (USD million)
TABLE 26 Colombia IVD market, by application, 2013 - 2024 (USD million)
TABLE 27 Colombia IVD market, by technology, 2013 - 2024 (USD million)
TABLE 28 Colombia IVD market, by end-use, 2013 - 2024 (USD million)
TABLE 29 Argentina IVD market, by product, 2013 - 2024 (USD million)
TABLE 30 Argentina IVD market, by application, 2013 - 2024 (USD million)
TABLE 31 Argentina IVD market, by technology, 2013 - 2024 (USD million)
TABLE 32 Argentina IVD market, by end-use, 2013 - 2024 (USD million)
TABLE 33 Venezuela IVD market, by product, 2013 - 2024 (USD million)
TABLE 34 Venezuela IVD market, by application, 2013 - 2024 (USD million)
TABLE 35 Venezuela IVD market, by technology, 2013 - 2024 (USD million)
TABLE 36 Venezuela IVD market, by end-use, 2013 - 2024 (USD million)